Dorzagliatin vs PB-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Dorzagliatin · Huatangning
Marketed by Hua Medicine under a licence from Roche
NCT04531631 · Phase 2 · completed
The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.
Reported efficacy
first phase insulin response to glucose (10 mins): Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). (missed)
Result source: NCT04531631
PB-201
Developed by PegBio and partners
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dorzagliatin | PB-201 |
|---|---|---|
| HbA1c, change | —Not posted · NCT03173391 | —Not reported |
| Body weight, change (kg) | —Not posted · NCT03173391 | —Not reported |
| HbA1c below 7% | —Not posted · NCT03173391 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT03173391 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT03173391 | —Not reported |
HbA1c, change
- Dorzagliatin
- —Not posted · NCT03173391
- PB-201
- —Not reported
Body weight, change (kg)
- Dorzagliatin
- —Not posted · NCT03173391
- PB-201
- —Not reported
HbA1c below 7%
- Dorzagliatin
- —Not posted · NCT03173391
- PB-201
- —Not reported
Fasting plasma glucose, change
- Dorzagliatin
- —Not posted · NCT03173391
- PB-201
- —Not reported
3-point MACE (% with event)
- Dorzagliatin
- —Not posted · NCT03173391
- PB-201
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PB-201: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dorzagliatin's landscape · PB-201's landscape